This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

This study has been completed.
Information provided by:
NeoStrata Company, Inc. Identifier:
First received: June 25, 2008
Last updated: November 17, 2008
Last verified: November 2008
The purpose of this study is to compare the safety and effectiveness of a new topical LCD solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms of plaque psoriasis and improving the quality of life in adults.

Condition Intervention
Chronic Plaque Psoriasis Drug: LCD Drug: calcipotriol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis

Resource links provided by NLM:

Further study details as provided by NeoStrata Company, Inc.:

Primary Outcome Measures:
  • Difference in percent reduction in Psoriasis Area and Severity Index (PASI) Scores between treatment arms [ Time Frame: 12 weeks of treatment ]

Secondary Outcome Measures:
  • Changes in PLASI, PEASI, Physician Global Assessment (PGA), Pruritus, and Dermatology Life Quality Index (DLQI) Scores between treatment arms [ Time Frame: Week 12 and Week 18 ]

Estimated Enrollment: 60
Study Start Date: January 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
LCD Solution: 2 applications / day
Drug: LCD
2 applications / day for 12 weeks
Active Comparator: 2
Calcipotriol cream: 2 applications / day
Drug: calcipotriol
2 applications / day for 12 weeks
Other Name: Dovonex Cream (50 mcg/g 0.005%)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • able and willing to provide written informed consent
  • diagnosed with chronic plaque psoriasis
  • 3% to 15% body surface area involved
  • in good general health

Exclusion Criteria:

  • other current treatments for psoriasis
  • renal or liver dysfunction
  • pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00705900

United States, Massachusetts
Mass General Hospital: Clinical Unit for Research Trials in Skin
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
NeoStrata Company, Inc.
Principal Investigator: Alexandra B Kimball, MD Massachusettes General Hospital / Brigham Women's Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Alexandra B. Kimball, MD, Massachusettes General Hospital / Brigham Women's Hospital Identifier: NCT00705900     History of Changes
Other Study ID Numbers: 06-LCDPOP
Study First Received: June 25, 2008
Last Updated: November 17, 2008

Keywords provided by NeoStrata Company, Inc.:

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Dermatologic Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 19, 2017